Hemoptysis (> ½ teaspoon [2.5 mL] of bright red blood) within 6 months prior to randomization
Severe, active co-morbidity defined as follows:\r\n* Current (within 28 days of cycle 1, day 1) signs and/or symptoms of bowel obstruction\r\n* Patients who require parental hydration and/or nutrition\r\n* Patients who require drainage gastrostomy tube\r\n* Evidence of bleeding diathesis or clinically significant coagulopathy\r\n* Serious, non-healing or dehiscing wound, active ulcer or untreated bone fracture\r\n* History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment
History of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months of starting study treatment
Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug
Pulmonary hemorrhage or gross hemoptysis (bright red blood of >= 1/2 teaspoon per episode) within 6 months prior to enrollment
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
Patients with history of hematemesis or hemoptysis (defined as having bright red blood of 1/2 teaspoon or more per episode) within 28 days prior to registration
History of pulmonary hemorrhage/hemoptysis >= grade 2 (defined as >= 2.5 mL bright red blood per episode) within 1 month prior to randomization.
History of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months prior to study treatment
(Bevacizumab-related exclusion) History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment for any tumor type
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) =< 28 days of study enrollment
History of hemoptysis (defined as > 1/2 tablespoon [tsp] of bright red blood per day)
Patients with hemoptysis (defined as bright red blood or >= 1/2 teaspoon) within 2 months prior to enrollment, or with central or cavitating lesions, will be excluded
History of pulmonary hemorrhage/hemoptysis >= grade 2 (defined as >= 2.5 mL bright red blood per episode) within 1 month prior to on-study date
Gastrointestinal bleeding or active hemoptysis (bright red blood of at least half teaspoon) within 3 weeks prior to the first dose of study drug.
History of hemorrhage or hemoptysis (> 1/2 teaspoon bright red blood) within 3 months of starting study treatment
History of hemoptysis ( >= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1 of FOLFIRI + bevacizumab initiation
Active hemoptysis (bright red blood of at least 0.5 teaspoon) or tumor bleeding within 3 weeks prior to the first dose of study drug
History of hemoptysis (? 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1
History of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months of starting study treatment
No active or recent hemoptysis (>= 1/2 teaspoon of bright red blood per episode) =< 30 days prior to registration
Patients are excluded if they have a history of hemoptysis (bright red blood of 1/2 teaspoon or more per episode) within 3 months prior to randomization
History of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months of starting study treatment
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment for any tumor type
Active hemoptysis (bright red blood of at least 2.5 mL ie, half teaspoon) within 3 weeks prior to the first dose of study drug.
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) or other significant spontaneous bleeding event within 1 month prior to day 1 of study drug or at any time on a prior VEGF inhibitor
Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5 teaspoon) within 28 days prior to randomization
Have a significant bleeding disorder or vasculitis or had a Grade ?3 bleeding episode within 12 weeks prior to enrollment. Participants with a history of gross hemoptysis (defined as bright red blood of ?1/2 teaspoon) within 2 months prior to enrollment are excluded.
Active or recent history of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) =< 30 days prior to registration/randomization
Gastrointestinal bleeding or active hemoptysis (bright red blood of at least half teaspoon) within 21 days prior to enrollment
Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks before the first dose of study drug.
History of hemoptysis (1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1.
No history of gross hemoptysis (defined as bright red blood of a half-teaspoon or more) within 3 months prior to enrollment
History of hemoptysis >= grade 2 (defined as bright red blood of at least 2.5 mL) =< 3 months prior to randomization
History of gastrointestinal (GI) bleeding (hemoptysis/melena/hematochezia, >= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day -3
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
History of uncontrolled hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
History of hemoptysis (greater than or equal to 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
History of hemoptysis ( >= 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1
History of hemoptysis (>/=1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1.
History of/or current evidence of hemoptysis (bright red blood of ½ teaspoon or more)
History of hemoptysis (? 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1
Patients with a history of gross hemoptysis (defined as bright red blood of ½ teaspoon or more) will be excluded from this trial
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1
History of hemoptysis (>= ½ teaspoon of bright red blood per episode) within 1 month prior to day 1
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
Active hemoptysis (bright red blood > 1 teaspoon on more than one occasion) =< 3 weeks prior to registration
Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.